Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cp-154526. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 1.00 |
| ▸ | FPR3 | P25089 | 2/20 | 1.00 |
| ▸ | TSPO | P30536 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cp-154526 SCHEMBL31012286 | 1.00 | CRHR1 (1.00) | CRHR1FPR3TSPOTMEM97TDP1 | |
| Cp-154526 SCHEMBL29706373 | 0.99 | CRHR1 (1.00) | CRHR1FPR3TSPOTMEM97TDP1 | |
| Cp-154526 SCHEMBL5707848 | 0.99 | CRHR1 (1.00) | CRHR1FPR3TSPOTMEM97TDP1 | |
| SCHEMBL5611306 | 0.92 | CRHR1 (0.87) | CRHR1FPR3TSPOTMEM97TDP1 | |
| SCHEMBL7610604 | 0.89 | CRHR1 (0.82) | CRHR1FPR3TSPOTMEM97TDP1 | |
| SCHEMBL6779979 | 0.89 | CRHR1 (0.82) | CRHR1FPR3TSPOTMEM97TDP1 | |
| SCHEMBL5600474 | 0.89 | CRHR1 (0.82) | CRHR1FPR3TSPOTMEM97TDP1 | |
| [18F]Fbppa SCHEMBL31438306 | 0.89 | CRHR1 (0.82) | CRHR1FPR3TSPOTMEM97TDP1 | |
| SCHEMBL6779312 | 0.88 | CRHR1 (0.80) | CRHR1FPR3TSPOTMEM97TDP1 | |
| SCHEMBL8362035 | 0.88 | CRHR1 (0.80) | CRHR1FPR3TSPOTMEM97TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656192-A2 | TILDACERFONT AND DERIVATIVES THEREOF FOR TREATING POLYCYSTIC OVARY SYNDROME | Spruce Biosciences, Inc. (US) | 2025-12-03 | — | — | EP | claimed |
| EP-4656192-A2 | TILDACERFONT AND DERIVATIVES THEREOF FOR TREATING POLYCYSTIC OVARY SYNDROME | Spruce Biosciences, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250206733-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2025-06-26 | — | — | US | disclosed |
| CN-118948857-A | Methods and compositions for treating polycystic ovary syndrome | 云杉生物科学公司 | 2024-11-15 | — | — | CN | disclosed |
| US-12098152-B2 | Methods and compositions for treating polycystic ovary syndrome | SPRUCE BIOSCIENCES, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| CN-116322544-B | Methods and compositions for treating polycystic ovary syndrome | 云杉生物科学公司 | 2024-08-02 | — | — | CN | disclosed |
| US-11858932-B2 | Methods and compositions for treating polycystic ovary syndrome | SPRUCE BIOSCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230322775-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-10-12 | — | — | US | disclosed |
| US-20230295161-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-09-21 | — | — | US | disclosed |
| CN-116322544-A | Methods and compositions for treating polycystic ovary syndrome | 云杉生物科学公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-114423436-A | Method for treating congenital adrenal hyperplasia | 云杉生物科学公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3986416-A1 | METHODS OF TREATING CONGENITAL ADRENAL HYPERPLASIA | Spruce Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-1293213-A1 | PREVENTIVES/REMEDIES FOR POSTOPERATIVE STRESS | JAPAN TOBACCO INC. (JP) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206733-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | CYP17A1, SHBG, NR5A1 | CRHR1 158/4885FPR3 2979/4885TSPO 4775/4885 |
| US-11858932-B2 | Methods and compositions for treating polycystic ovary syndrome | CYP17A1, SHBG, NR5A1 | CRHR1 158/4885FPR3 2979/4885TSPO 4775/4885 |
| US-20230322775-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | CYP17A1, SHBG, NR5A1 | CRHR1 158/4885FPR3 2979/4885TSPO 4775/4885 |
| US-12098152-B2 | Methods and compositions for treating polycystic ovary syndrome | CYP17A1, SHBG, NR5A1 | CRHR1 158/4885FPR3 2979/4885TSPO 4775/4885 |
| US-20230295161-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | CYP17A1, SHBG, NR5A1 | CRHR1 158/4885FPR3 2979/4885TSPO 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.